Skip to main
MD
MD logo

MEDNAX (MD) Stock Forecast & Price Target

MEDNAX (MD) Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 14%
Buy 14%
Hold 71%
Sell 0%
Strong Sell 0%

Bulls say

Pediatrix Medical Group has demonstrated robust financial performance with a 6.2% same-store growth in the first quarter of 2025, indicating strong momentum driven by pricing strength. The company anticipates margin upside and improved cash flow as a result of portfolio restructuring and a transition in revenue cycle management. Additionally, adjusted earnings per share estimates for 2025 and 2026 have been raised to $1.72 and $1.84, respectively, reflecting an optimistic outlook for the company's financial trajectory.

Bears say

Pediatrix Medical Group's stock is viewed negatively due to its heavy reliance on a declining birth rate in the U.S., which poses ongoing headwinds for revenue generation. The neonatal business is characterized by limited organic growth and potential challenges in achieving consistent margins, which raises concerns about sustainability. Additionally, internal complications arising from the compensation structure may hinder recruitment and growth, while external factors such as regulatory changes and reimbursement rate shifts could further adversely impact the company's financial performance.

MEDNAX (MD) has been analyzed by 7 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 14% recommend Buy, 71% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MEDNAX and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MEDNAX (MD) Forecast

Analysts have given MEDNAX (MD) a Hold based on their latest research and market trends.

According to 7 analysts, MEDNAX (MD) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MEDNAX (MD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.